Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded in late-stage trials, but the therapies did not clearly beat existing competitors on the market.
In the Phase 3 trials, dubbed Horizon and Mint, the California company tested therapies for eczema and myasthenia gravis, respectively. In its eczema trial, Amgen reported that its drug, rocatinlimab, outperformed a placebo in reducing outbreaks of red, itchy lesions. After 24 weeks, 32.8% of patients on the drug saw at least a 75% improvement in the extent and severity of skin lesions, compared to 13.7% of those taking a placebo, a metric dubbed EASI-75.
The drug also beat placebo in reducing overall disease severity as measured by two different doctors’ assessments, the validated investigator global assessment and the revised investigator global assessment. Amgen said the treatment was generally safe and well-tolerated.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
